What is FDMT's current stock price?

FDMT (4D Molecular Therapeutics, Inc.) is currently trading at $8.69 with a market cap of $454.0M.

What sector is 4D Molecular Therapeutics, Inc. in?

4D Molecular Therapeutics, Inc. (FDMT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is FDMT a good stock to buy?

Analysts have a Buy consensus on FDMT with a price target of $33.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

FDMT 4D Molecular Therapeutics, Inc.

Healthcare

$8.69+0.00%OpenMarket Cap: $454.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.30

P/S

5.09

EV/EBITDA

-2.22

DCF Value

$-10.93

FCF Yield

-28.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

-12.4%

Operating Margin

-203.5%

Net Margin

-182.3%

ROE

-36.8%

ROA

-31.4%

ROIC

-37.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.0M	$-68.8M	$—
Q4 null	$85.1M	$19.4M	$—
FY null	$85.2M	$-140.1M	$—
Q3 null	$90.0K	$-56.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$33.00

Target (Median)

$33.00

Target Range

$33.00 - $33.00

2 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-20

RBC CapitalOutperform

2026-03-19

Chardan CapitalBuy

2026-03-19

Chardan CapitalBuy

2025-12-18

BarclaysOverweight

2025-11-11

Trading Activity

Insider Trades

View All

Simms Christopher Paulofficer: See Remarks

SellFri Mar 27

Kirn Daviddirector, officer: Chief Executive Officer

SellFri Mar 27

Bizily Scottofficer: Chief Legal Officer

SellFri Mar 27

Gupta Ashooofficer: VP, Finance and Controller

SellTue Mar 24

Gupta Ashooofficer: VP, Finance and Controller

SellTue Mar 24

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.76

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Peers